Kinases as drug discovery targets in hematologic malignancies

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Protein kinases play a crucial role in cellular signaling pathways, and their dysregulation is implicated in various hematological malignancies.
• Targeting specific kinases has proven effective in treating certain blood cancers, exemplified by imatinib mesylate (Gleevec) for BCR-ABL-positive leukemias.

Purpose of the Study:

• To review novel protein kinase targets for drug discovery in hematological malignancies.
• To discuss kinases currently under preclinical and clinical investigation for targeted cancer therapy.

Main Methods:

• Literature review of preclinical and clinical studies on kinase inhibitors in hematological malignancies.
• Identification of emerging kinase targets across different blood cancer types.

Main Results:

• Several validated kinase targets exist, including BCR-ABL and FLT3.
• Novel targets identified include KDR, KIT, CSF-1R, RAS, RAF, JAK2 fusion protein, TIE-1, CDK modulators, ALK, mTOR, PDGF-R, FGF-R, and STAT3.
• The number of kinase-targeted therapies in clinical development has significantly increased.

Conclusions:

• Protein kinases represent a major focus for rational drug discovery in oncology.
• Ongoing research into novel kinase targets offers promising avenues for developing targeted therapies for hematological malignancies.